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HIV-1 envelope (Env) uses CD4 and a coreceptor (CCR5 and/or CXCR4) for viral entry. The efﬁciency of
receptor/coreceptor mediated entry has important implications for HIV pathogenesis and transmission. The
advent of CCR5 inhibitors in clinical use also underscores the need for quantitative and predictive tools that
can guide therapeutic management. Historically, measuring the efﬁciency of CD4/CCR5mediated HIV entry
has relied on surrogate and relatively slow throughput assays that cannot adequately capture the full
spectrum of Env phenotypes. In this review, we discuss the details of the Afﬁnoﬁle receptor afﬁnity
proﬁling system that has provided a quantitative and higher throughput method to characterize viral entry
efﬁciency as a function of CD4 and CCR5 expression levels. We will then review how the Afﬁnoﬁle system
has been used to reveal the distinct pathophysiological properties associated with Env entry phenotypes
and discuss potential shortcomings of the current system.
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Since human immunodeﬁciency virus type 1 (HIV-1) was
discovered as the causative agent of acquired immune deﬁciency
syndrome (AIDS), it has been estimated that 440 million people
have become infected with the virus and 420 million have died
of AIDS. Approximately 5 million new infections occur annually
(UNAIDS, 2008). The overwhelming majority of these individuals
live in third world countries with little or no access to antire-
troviral therapies. Moreover, HIV-1 is predicted to become the
leading burden of disease in middle and low income countries by
2015 (Colin and Dejan, 2006). Understanding how certain viral
features affect HIV-1 pathogenesis and transmission remains
essential to the development of more effective therapies, preven-
tion strategies, and vaccines.
The process of HIV-1 entry into cells of the immune system
begins with the viral gp120 envelope glycoprotein (Env) binding
to cellular CD4 and then subsequently to a coreceptor, which is
either of the chemokine receptors CCR5 or CXCR4. This initial
binding of gp120 to CD4 promotes the exposure of the coreceptor
binding site to facilitate CCR5 or CXCR4 binding. Upon coreceptor
binding, the Env undergoes further conformational changes that
reorient the gp41 glycoproteins to promote fusion between the
viral and cellular membranes, facilitating the deposition of the
viral contents into the cell cytoplasm. The principle steps of HIV-1
entry have been detailed in recent excellent review articles
(Melikyan, 2008; Wilen et al., 2012b, 2012a).
There are a multitude of host and viral factors that contribute to
the varied clinical outcomes of HIV-1-infected subjects. Among the
viral factors, it is unlikely that co-receptor tropism per se accounts
for viral pathogenicity. For subjects who harbor only CCR5-using
(R5) viruses throughout their disease, a large body of evidence
indicates the relative efﬁciency by which HIV-1 uses CD4 and CCR5
correlates with the pathogenic potential of the virus (Duenas-
Decamp et al., 2010; Gorry and Ancuta, 2011). For patients with R5
viruses, HIV disease progression has been associated with
enhanced macrophage (M)-tropism (Blaak et al., 2000; Li et al.,
1999; Trkola et al., 1996), the increased ability to use low levels of
CCR5 (Gray et al., 2005; Li et al., 1999; Smit et al., 2001; Tuttle
et al., 2002), and the increasing relative entry efﬁciency of the
infecting virus (Marozsan et al., 2005; Rangel et al., 2003).
Neurovirulence is also correlated with an isolates ability to use
low levels of CD4 and/or CCR5 present on microglial cells (Gorry
et al., 2002; Smit et al., 2001). Furthermore, R5-viruses derived
from late versus early disease not only show increased CCR5 usage
but also greater sensitivity to inhibition by various ligands or
antagonists of CCR5 (Gray et al., 2005; Koning et al., 2003; Kwa
et al., 2003; Lobritz et al., 2007; Olivieri et al., 2007). It is possible,
then, that a viral isolate capable of using minute amounts of CCR5
to infect may allow for expanded tropism of target cells, and
therefore, increased pathogenicity (Dejucq et al., 1999; Pakarasang
et al., 2006; Peters et al., 2007). Finally, in the SIVmac model, R5 SIV
strains can clearly become virulent without coreceptor switching
(Kimata et al., 1999a, 1999b). Thus, it seems likely that the relative
efﬁciency of CD4 and CCR5 usage during disease rather than a
simple switch from R5 to X4 co-receptor tropism is a better
predictor of viral pathogenicity.
Until recently our ability to quantify the efﬁciency of CD4 and
CCR5 usage has been limited by indirect and non-standardized
measures such as competition with soluble CD4, speciﬁc anti-
bodies, or chemokine receptor ligands. The development of new
tools, such as the Afﬁnoﬁle system, provides an unprecedented
ability to examine the mechanics and efﬁciency of CD4 and CCR5
mediated viral entry in greater detail, using a more quantitative
methodology, and with a higher throughput format, than was
previously possible. The Afﬁnoﬁle system, published in late 2009(Johnston et al., 2009), has been used in a number of studies that
have increased our understanding of how entry efﬁciency inﬂu-
ences HIV-1 pathogenesis and impacts on the clinical manage-
ment of disease using an evolving class of entry inhibitors.
Initial studies of HIV-1 entry examined the ability of labora-
tory adapted and primary viral isolates to grow on primary cell
cultures and CD4þ T cell lines (Dalgleish et al., 1984; Klatzmann
et al., 1984a, 1984b). These early studies led to the classiﬁcation
of HIV-1 laboratory and primary isolates according to their ability
to grow on primary macrophages (M-tropic), T cell lines (T-tropic)
or both (Dual-tropic). Although CD4 was discovered as a critical
receptor for HIV-1 entry soon after the discovery of HIV-1 as the
causative agent of AIDS, it was soon realized that CD4 alone was
not sufﬁcient to support HIV-1 entry (Chesebro et al., 1990;
Clapham et al., 1991; Kikukawa et al., 1986). A coreceptor was
required. When CCR5 and CXCR4 were identiﬁed as bona ﬁde
coreceptors for HIV entry, they were initially thought to be the
cognate coreceptors for all M- and T cell-tropic viruses, respec-
tively, with the implication that dual-tropic isolates used both
CCR5 and CXCR4. A new nomenclature re-designated M-, T-, or
Dual-tropic HIV-1 strains as R5, X4 or R5X4 viruses based on their
ability to enter cells expressing either or both coreceptors (Berger
et al., 1998). Initial studies that examined the efﬁciency of HIV-1
entry principally employed soluble factors, proteins and antibo-
dies as surrogate means to measure HIV-1 Env entry efﬁciency as
a function of the ability of the viral Env to infect cells in the
presence of each factor.
The study of HIV-1 entry efﬁciency in a more direct manner
was facilitated by the engineering of a series of HeLa cell based
lines by the Kabat laboratory (Kozak et al., 1997; Platt et al., 1998,
1997). A binary library of clonal cells was generated that
expressed ﬁxed amounts of CD4 and CCR5: all clones had either
high (HI-J, 105) or low (HI-R, 104) amounts of CD4, but individual
subclones within each CD4 library covered a spectrum of CCR5
expression levels. These cell lines provided a much needed tool to
determine whether a viral isolate required high levels of CD4 or
CCR5, or could scavenge relatively low levels of CD4 or CCR5 for
entry, and were a signiﬁcant improvement upon studies that used
transient transfection to generate differing CD4 and CCR5 levels.
Although these clonal cells have been used for multiple studies
comparing viral isolates for differences in their relative ability to
use CD4 and CCR5, most of the studies report relatively binary
information regarding whether a particular isolate can use high or
low levels of CD4 and/or CCR5. More importantly, the efﬁciency of
HIV-1 entry into cells within the human host likely results from a
complex interplay between the engagement of HIV-1 Env glyco-
proteins with the CD4 and CCR5 receptors, found at varying levels
on the surface of susceptible cells. The efﬁciency at which CCR5 is
used for entry may depend on the level of CD4 present and vice
versa, and this interdependency may vary between different viral
isolates from various cohorts.Afﬁnoﬁle system
Our understanding of HIV-1 entry has undergone signiﬁcant
reﬁnement in the past two decades. A growing body of evidence
suggests that there are nuances of HIV-1 entry phenotypes that
have gone unappreciated, largely due to the inherent limitations
of tools available to quantify such differences. To better under-
stand how CD4 and CCR5 expression levels inﬂuence HIV-1
infectivity, we created the Afﬁnoﬁle system (Johnston et al.,
2009). This system consists of a CD4 and CCR5 dual-inducible
cell line, and a mathematical approach to quantify the receptor
usage pattern and entry efﬁciency of Env, as a function of CD4
and CCR5 expression. Together this system has provided a
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in greater detail compared to previous methods. In this review,
we will discuss the details of the Afﬁnoﬁle system, and better
specify the biological meaning of the metrics used to quantify the
entry phenotype of Env. We will then review how different
groups have used the Afﬁnoﬁle system to reveal the distinct
pathophysiological properties associated with particular Env
entry phenotypes, discuss potential shortcomings of the current
system, and offer our opinion as to which future studies could
beneﬁt from the Afﬁnoﬁle system.
293 Afﬁnoﬁle cell line
At the crux of the 293 Afﬁnoﬁle system is a quadruple stable
cell line that can be effectively induced to express combinatorial
amounts of CD4 and CCR5 receptor levels. We generated this cell
line sequentially using the selective reagents and strategy indi-
cated in Fig. 1 (see legend). The cell line was single-cell cloned at
four different stages to select for a clone with low basal level of
expression and inducible expression that covers the physiologic
range of CD4 and CCR5 levels. Through this process, we eventually
generated a dual inducible cell line where CD4 and CCR5 expres-
sion could be regulated independently and simultaneously by
varying the concentration of tetracycline and Ponasterone A,
respectively. In practice, we have found that minocycline or
doxycycline offers a better degree of control over tetracycline
itself. For ease of reference, we will simply refer to tetracycline
induction unless otherwise stated. Ponasterone A is a potent
inducer of the synthetic ecdysone-inducible mammalian expres-
sion system that is used in our Afﬁnoﬁle cells (Saez et al., 2000).
Quantitative ﬂow cytometry (qFACS) is used to determine the
number of CD4 and CCR5 antibody binding sites (ABS)/cell. In the
absence of any inducing reagent, the basal levels of CD4 expres-
sion can range from 1800 to 5000 ABS/cell (Agrawal-Gamse et al.,Fig. 1. CD4 expression is controlled by the Tet-On system in which constitutive express
O-CMV promoter (3) in the absence of tetracycline. In the presence of tetracycline, the t
allowing CMV driven expression of CD4. CCR5 expression is controlled by the synthetic e
of the modiﬁed heterodimeric subunits of the insect nuclear hormone receptors VgEcR a
same plasmid (pcVgRXR) (2), but are shown simply as ‘‘ponTransAct’’ for clarity. In the p
A inducible promoter on pIND-R5 (4) consisting of 5  ecdysone/glucocorticoid respons
amounts of tetracycline and/or ponasterone A induces CD4 and/or CCR5 expression, res
described in the text. The inset represents the publications that speciﬁcally state the m
induced. The natural logarithms of CD4 and CCR5 cell surface concentrations (ABS/cell) a
the analytic methods used to quantify the efﬁciency of CD4/CCR5 usage. (For interpretat
version of this article.)2009; Johnston et al., 2009; Loftin et al., 2010; Tilton et al., 2010),
whereas basal CCR5 levels range between 1000 and 8000 ABS/cell
(Agrawal-Gamse et al., 2009; Johnston et al., 2009; Loftin et al.,
2010; Roche et al., 2011a; Tilton et al., 2010). The published
values for the maximally induced levels of CD4 and CCR5
from four to ﬁve independent labs are given in the inset tables
in Fig. 1.
While there appears to be some variability in the range of CD4
and CCR5 levels that can be induced, we (and others) have found
that the induced CD4 and CCR5 expression levels are generally
reproducible within a lab. Nevertheless, the induction range can
drift over time even in the same lab (compare Agrawal-Gamse
et al., 2009 to Tilton et al., 2010). The variability can be due to
procedural differences, cell passage number, and importantly, the
nature or quality of the fetal calf serum (FCS) used. We have
recommended the use of dialyzed FCS as the wide spread use of
antibiotics (such as tetracyclines) in the agricultural industry
might lead to trace amounts in the animal source used for FCS
production. In addition, we cannot exclude the presence of cross-
reactive small molecules in undialyzed fetal calf serum that might
activate the synthetic VgRXR receptor used in the ecdysone-
inducible system. Finally, we cannot exclude a systematic error
inherent in the manufacturers standards provided by the different
kits used for qFACs (see Lee and Doms, 2001 for a technical
discussion of parameters that might affect the accuracy of qFACs
measurements). Therefore, it is important that each operator
conducts qFACs on the Afﬁnoﬁle cells prior to infection to insure
consistent induction. However, Afﬁnoﬁle cells can be passaged for
about 3 months before the CD4/CCR5 inducibility becomes
unreliable. Regardless of the actual ABS/cell number that is
obtained, the functional control for reproducible inducibility is
whether a ‘‘standard’’ strain of R5 virus in each lab responds with
the same infectivity proﬁle as CD4 and CCR5 is induced. As will be
discussed below, the infectivity proﬁle of a given virus across aion of the tet transactivator from pcDNA/TR (1) represses expression from the Tet-
et transactivator is released from the Tet-O-CMV promoter on pcDNA5/TO-CD4 (3),
cdysone-inducible system in which the pon A transactivator, VgRXR (2), comprises
nd RXR. VgEcR and RXR are independently driven by constitutive promoters on the
resence of ponasterone A, the two subunits dimerize (VgRXR) and bind to the pon
e elements (5  E/GREs), driving expression of CCR5. Thus, the addition of varying
pectively. The induced surface levels of CD4 and CCR5 are quantiﬁed by qFACS as
aximal number of CD4 (red) and/or CCR5 (green) antibody binding sites (ABS)/cell
re indicated here for convenience. We will refer to these numbers when discussing
ion of the references to color in this ﬁgure legend, the reader is referred to the web
Table 1
Summary of publications using 293 Afﬁnoﬁle cells.












Adaptive mutations in a human
immunodeﬁciency virus type 1 envelope
protein with truncate V3 loop restore function
by improving interaction with CD4
Lab adapted V3 truncation mutant
compensates for inefﬁcient CCR5 usage by
efﬁcient use of CD4; gains ability to enter cells
at low levels of CD4
Yes Yes Agrawal-Gamse et al. (2009)
Cellular
tropism
An altered and more efﬁcient mechanism of
CCR5 engagement contributes to macrophage
tropism of Ccr5-using HIV-1 envelopes
Ability of Envs to enter low CCR5/moderate
CD4 induced cells are positively correlated
with macrophage tropism
No No Sterjovski et al. (2010)
Cellular
tropism
Constrained use of CCR5 on CD4þ
lymphocytes by R5X4 HIV-1: efﬁciency of Env-
ccr5 interactions and low CCR5 expression
determine a range of restricted Ccr5-mediated
entry
Ability to use low levels of CCR5 on Afﬁnoﬁle
cells is strongly correlated with R5-mediated
entry into primary lymphocytes for R5X4
viruses
No No Loftin et al. (2010)
Cellular
tropism
Macrophage-tropic HIV-1 variants from brain
demonstrate alterations in the Way Gp120
engages both CD4 and CCR5
Afﬁnoﬁle cells reveal that brain R5
macrophage(M)-tropic Envs can use limiting
levels of CD4 whereas non-M-tropic lymph
node R5 Envs cannot; VERSA metrics reveal
inter-subject phenotypic segregation of brain
from LN-derived Envs
Yes Yes Salimi et al. (in press)
Pathogenesis HIV-1 replication in the central nervous
system occurs in two distinct cell types
R5 macrophage-tropic viruses derived from
CSF have enhanced ability to enter CD4low/
CCR5high Afﬁnoﬁle cells compared to R5 T-cell
tropic viruses derived from the same
compartment
No No Schnell et al. (2011)
Pathogenesis Primary infection by a human
immunodeﬁciency virus with atypical
coreceptor tropism
Rare GPEK V3 crown motif found in T/F virus
impairs efﬁciency of CCR5 usage in vitro,
despite efﬁcient replication in vivo; reversion
to consensus GPGK motif restores ability to
use low levels of CCR5 on Afﬁnoﬁle cells
Yes Yes Jiang et al. (2011)
Pathogenesis Elite suppressor-derived HIV-1 envelope
glycoproteins exhibit reduced entry efﬁciency
and kinetics
Envs derived from elite suppressors (ES) use
CD4 and CCR5 less efﬁciently compared to
Envs derived from chronic progressors (CP)
Yes No n Lassen et al. (2009) nPhenotypes
conﬁrmed by VERSA metrics in
Johnston et al. (2009)
Entry
inhibitor
HIV-1 predisposed to acquiring resistance to
maraviroc (MVC) and other CCR5 antagonists
in vitro has an inherent, low-level ability to
utilize Mvc-bound CCR5 for entry
Precursor MVC-sensitive Env that gave rise to
many MVC-resistant Envs has low-level ability
to use MVC bound form of CCR5, which is
signiﬁcantly revealed as levels of CCR5 is
lowered on Afﬁnoﬁle cell line
No No Roche et al. (2011a)
Entry
inhibitor
HIV-1 escape from the CCR5 antagonist
maraviroc associated with an altered and less
efﬁcient mechanism Of Gp120 - CCR5
engagement that attenuates macrophage
tropism
In presence of maraviroc, MVC resistant clone
requires higher levels of CCR5 for efﬁcient
entry
Yes Yes Roche et al. (2011b)
Entry
inhibitor
A maraviroc-resistant HIV-1 with narrow
cross-resistance to other CCR5 antagonists
depends on both N-terminal and extracellular
loop domains of drug-bound CCR5
Rare in-vivo MVC resistant isolate can use
CCR5 very efﬁciently, even in presence of
inhibitor, provided that an adequate amount
of CD4 is present
Yes Yes Tilton et al. (2010)
Entry
inhibitor
HIV-1 resistance to CCR5 antagonists
associated with highly efﬁcient use of CCR5
and altered tropism on primarycd4þ T cells
Presence of inhibitor increases sensitivity of
MVC-resistant Env to changes in CCR5 levels;
this is reﬂected in altered vector metrics
(increased y and D) which corresponded with
altered T cell tropism ðTEM4TCMÞ in presence
of inhibitor
Yes Yes Pfaff et al. (2010)
Entry
inhibitor
Inefﬁcient entry of vicriviroc-resistant HIV-1
via the inhibitor-ccr5 complex at low cell
surface CCR5 densities
Expression levels of CCR5 inﬂuences entry
efﬁciency of VVC-resistant Env in the presence
of VVC; resistance is more apparent at high
CCR5 levels




A quantitative afﬁnity-proﬁling system that
reveals distinct CD4/CCR5 usage patterns
among human immunodeﬁciency virus type
1 and simian immunodeﬁciency virus strains
Original paper describing the Afﬁnoﬁle cell
system and use of the VERSA metrics for
proﬁling CD4/CCR5 usage efﬁciencies; VERSA
metrics conﬁrm and quantify the phenotypic
differences between ES and CP Envs described
in Lassen et al. (2009)
Yes Yes Johnston et al. (2009)- The
deﬁnitions of the VERSA metrics
in this review supercedes those
given in the original paper
Gene therapy Targeted transduction via CD4 by a lentiviral
uses clathrin mediated entry pathway
Novel Sindbis/ab envelope transduction of
cells is dependent on CD4 expression level
No No Liang et al. (2009)
Review R5X4 HIV-1 coreceptor use in primary target
cells: implications for coreceptor entry
blocking strategies
Review No No Loftin et al. (2010)
K. Chikere et al. / Virology 435 (2013) 81–9184range of CD4 and CCR5 levels can be quantiﬁed by the viral entry
receptor sensitivity analysis (VERSA) computational platform. We
will show that our analytic method somewhat mitigates the
variability inherent in our inducible biological system.This dual inducible cell line was dubbed the 293 Afﬁnoﬁle cells
to reﬂect its potential ability to measure the relative binding
afﬁnities of Env for CD4 and CCR5, and thus proﬁle the CD4 and
CCR5 usage efﬁciencies of HIV-1 (Johnston et al., 2009).
Fig. 2. (A) A prototypic R5 Env pseudotyped virus was used to infect Afﬁnoﬁle cells induced with varying concentration of tetracycline and ponasterone A. The infectivity
proﬁle generated in (A) can be mathematically ﬁtted to the surface function Fðx,yÞ shown in (B), where x and y are the mathematically rescaled values for the relevant CD4
and CCR5 concentrations (see text for details). Essentially, the surface plot in (B) represents the infectivity response of Env as a function of CD4 and CCR5 expression level,
which is described by the continuous polynomial function Fðx,yÞ. As indicated in the text, three parameters can be found to represent the salient features of the surface
function to capture the essential phenotypic behavior of Env in response to varying levels of CD4 and CCR5. The three metrics (1) mean infectivity M, (2) sensitivity vector
angle y, and (3) sensitivity vector amplitude D, are graphically represented in (B) and (C). The mathematical formulation of these metrics, their biophysical correlates, and
how these metrics can be used to quantify the entry phenotype of Env are detailed in the text. (D) A reproduction of Fig. 5 from Agrawal-Gamse et al. (2009) illustrating
how the nature of the infectivity plot is reﬂected in the angular metric. See text for details. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Using 293 Afﬁnoﬁle cells, the infectivity of a given Env, in the
context of a pseudotyped reporter virus, can be proﬁled across
24–48 distinct combinations of CD4 and CCR5 expression levels.
These various studies are listed in Table 1. The infectivity
proﬁle of a typical R5 virus infection across 25 distinct levels of
CD4/CCR5 expression levels is shown in Fig. 2A. To assist in
describing and comparing the infectivity data associated with
numerous viral Envs from various cohorts and research groups,
we created an automated computational web-based tool: Viral
Entry Receptor Sensitivity Analysis at versa.biomath.ucla.edu. For
a given Env, the VERSA program permits the rapid distillation
of the set of infectivity data points into three metrics that grossly
describe the Env’s CD4 and CCR5 usage pattern and entry efﬁciency.
Below, we will ﬁrst describe the analytical method used to
determine these metrics, and then deﬁne the biological meaning
of these metrics with respect to how they reﬂect the entry
phenotype of Env. We will then review the studies summarized
in Table 1 to illustrate how the Afﬁnoﬁle system, and the associated
VERSA metrics, can help reveal the distinct pathophysiological
Env phenotypes associated with differential CD4/CCR5 usage
efﬁciencies.Rescaling of CD4 and CCR5 expression levels: Since infectivities
were measured across numerous (typically 25–48) combinations
of CD4 and CCR5 concentrations, we sought to reduce the
dimensionality of the data into a geometrically meaningful form.
First, the experimentally relevant CD4 and CCR5 concentrations
















where ‘‘min’’ and ‘‘max’’ refer to the common minimum and
maximum receptor/coreceptor used across all measurements in a
given experiment. The variability represented by the differential
range of inducible CD4/CCR5 expression levels (when represented
in units of ABS/cell) is somewhat dampened by this rescaling,
where the minimum and maximum on both the x (CD4) and
y (CCR5) axes are deﬁned as 0 and 1, respectively. The use
of natural logarithms for this rescaling also effectively reduces
the magnitude of the variable expression levels (see inset tables
in Fig. 1).
Transformation of the raw infectivity data: The infectivity proﬁle
exhibited by a given viral Env across a spectrum of CD4 and CCR5
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Fig. 2A, can be mathematically ﬁtted to a corresponding 3-D
surface plot (Fig. 2B). The infectivity response as a function of CD4
and CCR5 expression level is described by the continuous poly-
nomial function
Fðx,yÞ ¼ aþbxþcyþdx2þey2þ fxy, ð2Þ
which represents the surface of the plot indicated in Fig. 2B. The
transformation of the raw infection data into the surface function
Fðx,yÞ using normalized infectivity data and rescaled CD4 and
CCR5 expression levels, allows us to deﬁne at least three para-
meters that quantify the ﬁtted data surface Fðx,yÞ. These three
parameters capture the salient topographical features of the
surface plot in Fig. 2B, which represents the phenotypic response
of Env to varying levels of CD4 and CCR5. We will now describe
how these three metrics are derived and computed in VERSA,
describe their mechanistic interpretation, and specify how they
are used to quantify the entry phenotype of Env.
VERSA metrics: The mean infectivity, M, provides a rough
estimate of the overall efﬁciency of entry; it is the mean of the
normalized function Fðx,yÞ across the entire range of CD4 (x) and






Fðx,yÞ dx dy, ð3Þ
and is graphically represented by the height of the square plane
(red) indicated in Fig. 2B.
Additional geometric features of the surface function can be







r!Fðx,yÞ dx dy Sxx^þSyy^ ð4Þ
which represents the average, across the relevant CD4 and CCR5
levels, of the local gradient vector on the surface. The vector S
!
encodes the overall direction of the infectivity surface and its
overall steepness (Fig. 2C). These can be represented by two
metrics: the sensitivity vector angle, y, and the vector amplitude,
D 9 S!9. Speciﬁcally, the overall direction of the sensitivity vector





The angle y is a measure of the relative infectivity response to
changes in CD4 versus CCR5 levels. A virus that is predominantly
sensitive to changes in CCR5 levels and not CD4 will have y near
901, while y 01 for a virus that is only sensitive to changes in
CD4 levels but not CCR5. A virus equally sensitive to changes in
both CD4 and CCR5 levels would have y 451.
The amplitude of the sensitivity vector D 9 S!9 measures the
overall ‘‘steepness’’ of the normalized infectivity function Fðx,yÞ,
averaged across the entire matrix of CD4 and CCR5 expression
levels; it measures the combined rate of increase of infectivity as
a function of CD4 and coreceptor concentrations. The vector
amplitude D is graphically represented by the length of the
sensitivity vector in Fig. 2C. This metric was previously termed
the vector ‘‘magnitude’’ (Johnston et al., 2009), which has the
unfortunate coincidence of starting with the letter ‘‘m’’, and may
lead to confusion with the mean infectivity metric M, which is
clearly distinct. Here, we formally designate the three metrics
described in Fig. 2B and C as mean infectivityM, sensitivity vector
angle y, and sensitivity vector amplitude D. These designations
will be changed accordingly in the updated version of VERSA.
Finally, note that M,y, and D can all be explicitly written in terms
of simple functions of the ﬁtting parameters fa,b,c,d,e,f g, and
thereby explicitly encodes the geometric features of the data
function Fðx,yÞ.Inputting normalized or raw infection data
VERSA supports the input of normalized or raw infection data
(e.g., RLU if using luciferase reporter viruses). Since our metrics
fM,y,Dg are all dimensionless, the actual type of infection data
used (RLU, or %GFPþ cells, or %p24þ cells, etc.) to obtain the
VERSA metrics is immaterial as long as the same type of data is
consistently used between experiments for comparisons. Given
this ﬂexibility, it is important to understand the impacts or
constraints that various kinds of input data may have on each
metric. While the vector angle y is insensitive to the use of raw or
normalized infectivity data, this is not true for mean infectivity M
and vector amplitude D. For example, since raw RLU data can
have a large dynamic range ( 325 logs), mean infectivity and
vector amplitude differences between viral Envs can be magni-
ﬁed. In these cases, Afﬁnoﬁle assays can be sensitive and relative
comparisons of Env phenotypes in the same lab are possible and
probably meaningful. However, the numbers obtained have no
independent meaning outside of a particular comparison cohort
in a particular lab. This is because RLUs can be affected by
arbitrary factors such as instrumentation sensitivity, integrated
time of detection, concentration and quality of the substrate used,
variations in room temperature, and a host of other systematic
errors that may be particular to the experiment.
On the other hand, if input data are normalized to the
maximum infectivity (set at 100%) obtained in each proﬁling
experiment, comparisons between divergent cohorts and infec-
tivity conditions may then be possible. However, normalization
assumes that infectivity plateaus at maximally induced CD4 and
CCR5 levels for a given Env, which is not always the case. Thus,
the VERSA metrics obtained using normalized data may be less
sensitive for detecting more subtle phenotypic differences in
entry efﬁciencies. We will discuss speciﬁc instances where
successful data interpretation has been obtained with one but
not the other kind of input data.
Current publications using Afﬁnoﬁle system
Next, we review how the Afﬁnoﬁle system has been used to
study (1) compensatory phenotypes mediated by unusual muta-
tions and truncations in HIV-1 Env, (2) relationship between
differential entry efﬁciencies and HIV disease pathogenesis,
(3) the inﬂuence of entry inhibitors on CD4 and CCR5 usage
patterns, and (4) the relationship between tropism and CD4/CCR5
usage. These studies are summarized in Table 1. In any given study,
many lines of evidence are usually provided to support the authors’
main conclusions. For the purposes of this review, we will mainly
focus on the evidence provided by the Afﬁnoﬁle system. We do
so in order to illustrate the phenotypic nuances that this system
can reveal, and to highlight how the use of Afﬁnoﬁle cells can
complement existing methodologies to gain a better understand-
ing on R5 virus tropism and pathogenesis. It is not our intention to
suggest that the evidence provided by the Afﬁnoﬁle system is of
paramount importance in any given situation. We do, however,
hope to show that the Afﬁnoﬁle system is a relatively convenient
and high throughput way of evaluating HIV R5 Env phenotypes in a
quantitative and reproducible fashion.Results and discussion
Compensatory phenotypes mediated by unusual mutations and
truncations in HIV-1 Env
The gp120 protein of HIV-1 Env includes ﬁve conserved
(C1–C5) and variable (V1–V5) regions. The conserved regions,
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of gp120. The variable regions, found on the outer domain, act as
an evolving shield for the virion against the immune response.
Of all the variable regions, the V3 loop of HIV-1 gp120 has long
been recognized as being particularly important due to its dual
role in protecting the Env from neutralizing antibodies, as well as
in determining coreceptor choice (Zolla-Pazner and Cardozo,
2010). Mutations and truncations in V3 usually result in an Env
that is unable to promote entry, despite seemingly proper protein
folding (Wyatt et al., 1993). In Agrawal-Gamse et al. (2009),
the authors discovered that a dual tropic virus, termed R3A, could
tolerate a deletion of 15 amino acids that removed the central
portion of the V3 loop. This virus with the truncated Env, termed
V3(9,9), was severely compromised in its ability to infect SupT1CCR5
cells compared to the parental R3A Env. Subsequent passage of the
V3(9,9) virus on SupT1CCR5 cells, which express high levels of
CCR5, partially restored the entry efﬁciency of the virus. Interest-
ingly, the adapted virus, named TA1, retained the V3 truncation
while gaining several other mutations and deletions in other
areas of the Env.
In a vivid and elegant demonstration, the Doms lab used the
Afﬁnoﬁle cells to proﬁle the infectivity of the parental R3A virus,
the initial V3(9,9) truncation mutant with compromised function,
and the ﬁnal TA1 virus adapted to grow well on SupT1-CCR5 cells.
The infectivity plots (reproduced in Fig. 2D) reveal that the initial
V3 truncation severely compromised R3A’s ability to efﬁciently
use low levels of CCR5. V3(9,9) no longer enter cells at low levels
CCR5 (0.016–0:063 mM Pon A) no matter how much CD4 was
provided. This defect was maintained in the adapted TA1 virus
Env. Instead, the infectivity proﬁle on Afﬁnoﬁle cells revealed that
the partially restored function of the TA1 virus Env was due to an
increased ability to use low levels CD4 (0.16–0.31 ng/ml minocy-
cline), provided that a sufﬁcient amount of CCR5 was present. The
gestalt of the infectivity proﬁles between these three mutants is
captured by angle metric y. Thus, R3A, which responds more
readily to changes in CD4 levels (at all levels of CCR5) has a y of
221, while the adapted TA1, which is now more responsive to
changes in CCR5 levels has a y of 691. Note that an increase in the
angular metric (towards 901) simply means an increased infectiv-
ity response to changes in CCR5 levels (and vice versa for CD4). An
increase or decrease in y by itself says nothing about whether the
change is due to more or less efﬁcient usage of CCR5 or CD4. The
angular metric needs to be interpreted in the context of the
infectivity proﬁle in order to make statements about receptor
usage efﬁciencies. In this case, the authors rightfully point out
that the scale on the z^-axis, representing the efﬁciency of entry as
reported by luciferase activity, clearly indicates that the adaptive
mutations in TA1 increased its infection efﬁciency over V3(9,9) by
about 10-fold, mainly by enhancing the its ability to use low
levels of CD4. These Afﬁnoﬁle data are consistent with the
cumulative results from the myriad other inhibition and time-
of-addition experiments conducted in this study.
Relationship between differential entry efﬁciencies and HIV disease
pathogenesis
Using the Afﬁnoﬁle cell line and system, several publications
have discovered differences between HIV-1 pathogenic categories
that can be ascribed to disparities in entry efﬁciencies; disparities
that are not always revealed by conventional entry assays.
Elite suppressor vs. chronic progressor Envs
In Lassen et al. (2009), the authors used the Afﬁnoﬁle cells to
examine a total of 70 Envs derived from chronic progressor (CP)
and elite suppressor (ES) HIVþ subjects. The results of thesestudies revealed that, on average, ES Envs are less efﬁcient at
using both CD4 and CCR5, when compared to CP Envs. Thus, when
CCR5 levels were ﬁxed, and CD4 levels varied or vice versa, ES Env
pseudotypes achieved a moderately lower level of infection
relative to CP Envs. Notably, due to the large variations in IC50’s
between individual Env clones, even among clones from the same
patient, there was no signiﬁcant difference between ES and CP
Envs in their sensitivity to CCR5 antagonism (via CCL5 (RANTES)
or TAK779) or fusion (Enfuvirtide) inhibition. However, when the
infectivity data were reexamined using VERSA (Johnston et al.,
2009), the mean infectivity M and vector angle y were signiﬁ-
cantly higher for CP Envs compared to ES Envs. The data also
indicate that the increased M values of the CP Envs were
associated with their increased responsiveness to changes in
CCR5 levels (higher y values). Together, the Afﬁnoﬁle data
(increased M with increased y) suggest that the increased respon-
siveness of the CP Envs to changes in CCR5 levels was likely due to
their increased efﬁciency of CCR5 usage. Inspection of the infec-
tivity plots conﬁrmed this interpretation. As mentioned earlier,
this increased efﬁciency of CCR5 usage was not evident using
conventional inhibitor assays, as ES and CP Envs did not show
differential susceptibility to CCL5 (RANTES) or TAK779.
Central nervous system-derived Envs
The ability of the Afﬁnoﬁle system to phenotypically segregate
potential pathogenic categories is supported by the following two
studies. In Schnell et al. (2011), the authors demonstrated that R5
HIV-1 isolated from cerebral spinal ﬂuid (CSF) of patients with or
without HIV-1 associated dementia (HAD) segregated into two
phenotypic categories: the ability or lack thereof to infect Afﬁno-
ﬁle cells induced at CD4low/CCR5high levels. Viral isolates that can
infect CD4low/CCR5high Afﬁnoﬁle cells can also infect monocyte
derived macrophages (MDM), and thus are R5 M-tropic. Alter-
natively, isolates that can only infect CD4high/CCR5high but not
CD4low/CCR5high Afﬁnoﬁle cells, can also only infect activated
CD4þ T-cells, but not MDM, and thus are R5 T-tropic. The authors
observed that CSF-derived viruses isolated from patients with
HAD could be either R5 T cell-tropic and/or R5 M-tropic whereas
viruses isolated from patients without HAD are invariably R5 T
cell-tropic. Although the study is small and involved only eight
HAD patients, at least for the cohort examined, it appears that the
ability of infect CD4low/CCR5high Afﬁnoﬁle cells at 410% levels
relative to CD4high/CCR5high Afﬁnoﬁle cells can be as sensitive a
marker for detecting R5 M-tropic viruses as using MDM infection
itself. Interestingly, in longitudinal samples from one patient, the
authors were able to show that CSF-derived R5 M-tropic Envs that
could infect CD4low/CCR5high Afﬁnoﬁle cells could be detected
many months prior to subsequent HAD diagnosis.
More recently, Salimi et al. (in press) examined brain (BR) and
lymph nodes (LN) Envs derived from patients that succumbed to
HAD. Using the Afﬁnoﬁle system the authors reveal that R5
macrophage (M)-tropic BR Envs can use limiting levels of CD4
whereas R5 non-M-tropic LN Envs cannot. Furthermore, a combi-
nation of all three VERSA metrics clearly revealed inter-subject
phenotypic segregation of BR- from LN-derived Envs, which
occurred independent of genetic signature alterations. Inter-sub-
ject genetic signature alterations associated with HIV-1 compart-
mentalization have not been identiﬁed in previous studies,
principally because the functional affects of amino acid altera-
tions in gp120 are usually strain-speciﬁc. However, the mathe-
matical formulations and the normalization techniques that were
used to derive the VERSA metrics serve to quantify some intrinsic
functional properties of Env, which are more likely to be con-
served among Envs derived from different tissue sources. These
metrics can therefore be used to identify conserved phenotypic
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proﬁles.
Acute transmitted/founder virus Envs
However, the efﬁciency of CD4 and CCR5 usage, or the ability
to use low levels of (co)-receptors, does not always correlate with
the in vivo pathogenic potential of a viral isolate. In a recent study
by Jiang et al. (2011), the authors isolated and examined an
unusual R5 subtype B transmitter/founder (T/F) viral Env with a
rare motif in the V3 crown. In vivo, this virus replicated very
efﬁciently as shown by a high viral load during the time of acute
primary infection (4107 RNA copies/ml during Feinberg stage
III). However, examination of the Env entry phenotype using the
Afﬁnoﬁle system showed that this particular Env used CCR5 very
inefﬁciently, requiring high levels of both CD4 and CCR5 for
efﬁcient entry (y close to 451). Additionally, mutating the rare
GPEK V3 crown motif of the T/F Env to the consensus subtype B
motif, GPGK, conferred greater ability to use CD4 and CCR5 on
Afﬁnoﬁle cells, as well as other cell lines and primary cells. The
reversion to the consensus V3 crown motif ðGPEK-GPGKÞ was
accompanied by a marked decrease in y ð451-01Þ and a 10-fold
increase in D. Inspection of the infectivity proﬁle (Fig. 10 of the
paper) revealed that the GPGK reversion mutant is only sensitive
to changes in CD4 levels (hence y 01). The increase in D could be
accounted for by the accumulated increase of the infectivity
response at low levels of CCR5 (as CD4 levels are increased)
where no infectivity response was previously present. The
authors suggest the decrease in entry efﬁciency exhibited by this
viral isolate may be due to usage of coreceptors other than CCR5
and CXCR4, or to abnormal coreceptor protein conformation, both
of which are known to occur in vitro (Berro et al., 2011; Nedellec
et al., 2009). This illustrates the possible dichotomy between in vivo
and in vitro results.
Together, these studies demonstrate that the Afﬁnoﬁle system
can be effectively used to examine, characterize and/or segregate
the entry phenotypes of viruses that are associated with distinct
pathophysiological properties in vivo.
Inﬂuence of entry inhibitors on CD4 and CCR5 usage
The clinical use of CCR5 antagonists was initially accompanied
by concerns that resistance could easily occur by co-receptor
switching of the virus to the more pathogenic CXCR4-using
variants. These concerns were substantiated by the observation
that in vitro co-receptor switching can occur due to mutations of as
little as one amino acid (Pastore et al., 2004). Indeed, phenotypic
and/or genotypic testing for coreceptor tropism is required before
the use of maraviroc, currently the only FDA approved CCR5
antagonist, in combination antiretroviral therapy (Lin and
Kuritzkes, 2009). In earlier clinical trials, the development of
resistance to CCR5 antagonist was confounded by the relative
insensitivity of the phenotypic coreceptor tropism test (troﬁle),
which inadvertently allowed the outgrowth of pre-existing X4 or
dual-tropic/mixed (D/M) strains (Lin and Kuritzkes, 2009; Wilkin
and Gulick, 2012). In the absence of pre-existing X4 or D/M strains,
the preferred pathway to resistance for R5 strains appears to be
evolving the ability use the antagonist bound form of CCR5 rather
than bona ﬁde coreceptor switching (Westby, 2007). Several groups
have used the Afﬁnoﬁle system to shed more light on how HIV-1
circumvents entry inhibition mediated by CCR5 antagonists.
MPI and CCR5 expression levels
In one of the ﬁrst studies that used the Afﬁnoﬁle cell line
(Pugach et al., 2009), the authors examined how the expressionlevels of CCR5 can alter the maximum percent inhibition (MPI) of
viral isolates resistant to the CCR5 antagonist vicriviroc (VVC).
MPI indicates a plateau level of inhibition in the presence of
excess of inhibitor, and is a mechanistically distinct from resis-
tance that is attributed to increases in IC50. A MPI effect is
indicative that the virus is using the inhibitor-bound form of
CCR5. The results of this study demonstrated that the CCR5
expression levels were inversely proportional to the resulting
MPI, indicating that increasing levels of CCR5 can compensate for
the inefﬁcient usage of the inhibitor-bound form of CCR5 by VVC-
resistant viruses. Interestingly, two different VVC-resistant clones
independently derived from the drug sensitive parental clone
(CC1/85) can exhibit differential levels of VVC-resistance that is
revealed by the gradient of the MPI effect observed under varying
levels of CCR5 in the Afﬁnoﬁle cells. The authors suggest that the
CCR5 levels expressed on different cell lines or primary cells can
lead to distinct MPI plateaus, thus altering ones interpretation of
the degree of resistance.
These results were recently corroborated by Roche et al.
(2011a), which reported that the commonly used ‘‘maraviroc
(MVC) sensitive’’ CC1/85 Env (the parental derivative of many
CCR5-inhibitor resistant clones) has an inherent, albeit low-level,
ability to use the MVC-bound form of CCR5. The authors show
that when using U87-CD4/CCR5, JC53, TZM-bl cells and PBMC, the
MVC-sensitive CC1/85 virus is completely inhibited by saturating
concentrations of MVC, hence the MPI is 100 in these cells.
However, when the same experiment was done in NP2-CD4/
CCR5 cells, which express comparatively higher levels of CCR5, or
Afﬁnoﬁle cells induced to express high levels of CCR5, the MPI is
96.2% and 53%, respectively. Moreover, the authors show that
systematically decreasing the levels of CCR5 on Afﬁnoﬁle cells
gradually increases the MPI to the levels seen in the other cells,
thus illustrating an inverse relationship between the MPI and
CCR5 expression levels by this ostensibly ‘‘MVC-sensitive’’ CC1/85
Env. The authors suggest that this low level ability to use the
MVC-bound from of CCR5, which is only revealed on cells capable
of expressing high levels of CCR5, likely predisposes the CC1/85
Env to gaining (cross)-resistance to CCR5 antagonists. The robust
inverse correlation of MPI with CCR5 induction levels suggests
that the Afﬁnoﬁle cells may detect baseline resistance to CCR5
antagonists with greater sensitivity than the other commonly
used cell lines. If validated, this would facilitate the clinical use of
CCR5 inhibitors. The gradient of MPI observed as CCR5 is induced
on the same cellular background is a particularly useful property.
Conversely, U87-CD4/CCR5 cells that are commonly used for
phenotypic testing of CCR5 inhibitor resistance may not be
sensitive enough to detect the incipient development of CCR5
inhibitor resistance.
VERSA metrics reveal inefﬁcient use of inhibitor-bound CCR5 by
inhibitor resistant Envs
Using the Afﬁnoﬁle system, several groups have examined
how resistance to CCR5 entry inhibitors inﬂuences viral usage of
CD4 and CCR5. In Pfaff et al. (2010) and Roche et al. (2011b), the
authors detailed how in vivo and in vitro derived Envs resistant to
the CCR5 antagonists aplaviroc (APL) and MVC, respectively, have
modiﬁed entry efﬁciencies in the presence of the inhibitor. In
both studies, the authors showed that inhibitor sensitive and
resistant Envs, in the absence of any inhibitor, had similar 3-D
infection plots and vector metrics, highlighted by vector angles
ranging from 101 to 171, which implies a below average depen-
dency on CCR5 expression levels. However, examination of the
inhibitor resistant clones in the presence of inhibitor resulted in
infectivity plots with an overall reduced infection, but more
importantly the vector angles shifted to 231–301. Additionally,
K. Chikere et al. / Virology 435 (2013) 81–91 89the presence of the CCR5 antagonist reduced the non-normalized
‘‘vector magnitude’’ (now termed vector amplitude D) of the
resistant Env. Remarkably, in both cases, the presence of CCR5
inhibitor (APL or MVC) decreases the D values of the resistant
Envs by about 30%: 6 106 to 4 106 in Pfaff et al. (2010), and
1:56 105 to 1:05 105 in Roche et al. (2011a, 2011b). Thus, an
increase in vector angle y combined with a corresponding
decrease in absolute vector amplitude D indicates that the
apparent increase in CCR5 dependency (increase in y) is due to
more inefﬁcient use of CCR5, as revealed by the associated
decrease in D (lower overall rate of increase in the infectivity
response). These results together indicate that the resistant Envs
have an overall inefﬁcient usage of the inhibitor bound form of
CCR5. In both cases the reduced entry efﬁciency calculated by the
Afﬁnoﬁle cell system correlated with reduced and altered entry
into primary cells; more speciﬁcally, the Pfaff study showed an
altered tropism in CD4þ T cell subsets, while the Roche study
showed an attenuated tropism for macrophages, both due to the
reduced ability of resistant Envs to interact with drug-bound form
of CCR5.
Finally, in a separate study, Tilton et al. (2010) examined CCR5
antagonist sensitive and resistant clones isolated from a patient
who experienced virological failure on MVC. In the absence of
inhibitor, the sensitive and resistant clones had vector angles that
were similar, 6.71 and 7.61, respectively. As expected, in the
presence of inhibitor, infection with the sensitive clone was
completely abrogated. However, unlike the previous reports,
infection with the resistance clone was largely unaffected in the
presence of inhibitor, as revealed by a similar vector angle of 7.21,
indicating a highly efﬁcient usage of the drug-bound form of CCR5
by this particular resistant HIV-1 variant. Inspection of the
infectivity plots conﬁrmed that the MVC-resistant clone remained
sensitive only to changes in CD4 levels. This latter study illus-
trates that CCR5 antagonist resistance can occur with diametri-
cally opposed consequences on entry efﬁciency, as well as the
power of the VERSA metrics to reveal such opposing differences.
Cellular tropism and efﬁciency of CD4/CCR5 usage
In Loftin et al. (2010), the authors showed that dual-tropic
Envs have varying degrees of CCR5 usage in the absence of CXCR4
by infecting Afﬁnoﬁle cells expressing ﬁxed levels of CD4, and
varying levels of CCR5. Moreover, the authors show that the
ability of dual-tropic Envs to mediate entry into CD4high/CCR5low
induced Afﬁnoﬁle cells correlates with the efﬁciency of CCR5
mediated entry into lymphocytes. These results, coupled with
other assays convincingly, demonstrate that the use of CCR5 on
primary T-cells by dual-tropic Envs is positively correlated with
their CCR5 usage efﬁciency in Afﬁnoﬁle cells. Similarly, in a
separate study, Sterjovski et al. (2010) were able to show that
the ability of R5 primary isolates to enter MDM correlates with
the ability to enter Afﬁnoﬁle cells induced to express low levels of
CCR5 and moderate levels of CD4. These results, as well as the
reports discussed earlier, show that the Afﬁnoﬁle cell line may be
useful as a surrogate to examine entry into primary cells as well
as several other cell lines.
Limitations of 293 Afﬁnoﬁle system
Potential users should be aware of the inherent limitations and
constraints on the use of the 293 Afﬁnoﬁle system. For example,
we have determined that this cell line is not appropriate for
conducting b-lactamase based virus–cell fusion assays because
of the relatively high background levels (unpublished data).
We suspect that the ampicillin resistance genes, on each plasmid
used to make the quadruple stable cell line, collectively expressenough b-lactamase to increase the background level of CCF2-AM
cleavage. Issues such as this should be considered before the
using Afﬁnoﬁle cells outside designated parameters. As with
many cell lines, Afﬁnoﬁle cells express a basal level of CXCR4
that comes from its HEK 293 parentage. Therefore, it is critical
that the viral Env being examined is fully CCR5-dependent. This
can be conﬁrmed by the use of suitable CCR5 inhibitors; infection
on the Afﬁnoﬁle cells should be abrogated by a known CCR5-
inhibitor, or at least not affected by a known CXCR4-inhibitor.
Alternatively, as done by previous authors, saturating amounts of
CXCR4 entry inhibitor can be added to each well, preventing the
use of CXCR4 for entry. However, if the objective of the experi-
ment is to examine the efﬁciency of CD4 usage for CXCR4 viruses,
the basal level of CXCR4 present in the cell will permit this, as the
X4 Env HxB effectively gives infectivity plot with a vector angle
close to zero degrees (unpublished data). Finally, to obtain VERSA
metrics that meaningfully reﬂect the entry phenotype of a given
Env, we recommend that the infectivity proﬁle be determined
across at least 24 distinct combinations of CD4/CCR5 expression
levels.Conclusions
We have reviewed all published studies that have used the
Afﬁnoﬁle cells to reveal some new facet of the HIV entry process.
We invite the reader to inspect the original articles summarized
in Table 1. While expression levels of CD4 and CCR5 clearly
impacts on the efﬁciency of R5 HIV-1 entry, they are clearly not
the only host cell determinants that impact on the entry process.
However, of the various soluble host cell factors that have been
described to modulate HIV entry such as galectin-1 (Sato et al.,
2012; St-Pierre et al., 2011, 2010), galectin-9 (Bi et al., 2011), and
25-hydroxycholesterol (Liu et al., in press), it would be of great
interest to see if they do so in a manner dependent on CD4 and
CCR5 expression levels. The VERSA website at versa.biomath.ucla.
edu continues to accept suggestions as to further improvements,
and we are working on developing more robust methods to
facilitate more widespread usage of the Afﬁnoﬁle system. The
Afﬁnoﬁle system will be deposited in the NIH AIDS Reagent
Repository by early 2013.Acknowledgments
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